Skip to Content

News & Events

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Vertex Pharmaceuticals Announces Pricing of its Concurrent Public Offerings of Common Stock and Convertible Senior Subordinated Notes
CAMBRIDGE, Mass., Feb 12, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has entered into an agreement to sell 6,000,000 shares of its common stock in an underwritten offering at a price to the public of $17.14 per share.
View HTML
Toggle Summary Vertex Pharmaceuticals Reviews 2008 Business Priorities and Reports 2007 Financial Results
-- Focused on first-to-market opportunity with HCV protease<br> inhibitor telaprevir --<br><br> -- Additional drug candidates directed at HCV, cystic fibrosis and<br> immune-mediated diseases--
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Subordinated Notes
CAMBRIDGE, Mass., Feb 11, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it intends to offer, subject to market and other conditions, 6,000,000 shares of its common stock in an underwritten public offering under an automatically effective shelf
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Webcast of its Presentation at the BIO CEO & Investor Conference 2008
CAMBRIDGE, Mass., Feb 08, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the BIO CEO &amp; Investor Conference 2008 on Tuesday, February 12, 2008 at 10:15 a.m. EST.
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Webcast of its Presentation at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
CAMBRIDGE, Mass., Jan 31, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology &amp; Medical Device Conference on Tuesday, February 5, 2008 at 11:40 a.m.
View HTML
Toggle Summary Vertex Pharmaceuticals Announces the Date of its Fourth Quarter and Full Year 2007 Financial Results Conference Call and Webcast
CAMBRIDGE, Mass., Jan 28, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its fourth quarter and full year 2007 financial results on Monday, February 11, 2008 after the financial markets close. The Company will host a conference call at 5:00 p.m. EST.
View HTML
Toggle Summary Vertex Pharmaceuticals to Begin Phase 3 Development of Telaprevir, Investigational Hepatitis C Protease Inhibitor
-- Primary Phase 3 trial will focus on studying 24-week telaprevir-based regimens -- Vertex plans concurrent second study to support registration -- Final data from both trials anticipated in mid- 2010
HCV
View HTML
Toggle Summary Vertex Pharmaceuticals Reports Progress in Development of Investigational HCV Drug Telaprevir and Provides Business Update
- Formal European scientific advice obtained for telaprevir development program - - Meeting scheduled with FDA for January 2008 on Phase 3 trial design and recent data - - Next-generation HCV protease inhibitor and two investigational compounds for cystic fibrosis in clinical development -
HCV
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Webcast of its Presentation at the 26th Annual JPMorgan Healthcare Conference
CAMBRIDGE, Mass., Jan 03, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 26th Annual JPMorgan Healthcare Conference on Monday, January 7, 2008 at 2:00 p.m. PST (5:00 p.m. EST).
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Webcast of its Presentation at the CIBC World Markets 3rd Annual Mid & Small Cap 'Best Ideas' Conference
CAMBRIDGE, Mass., Nov 21, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the CIBC World Markets 3rd Annual Mid &amp; Small Cap 'Best Ideas' Conference on Wednesday, November 28, 2007 at 8:45 a.m. EST.
View HTML